Ash Alizadeh, MD, PhD

Ash Alizadeh is a cofounder of Foresight Diagnostics and Professor of Medicine (Oncology) at Stanford University, where he leads the Cancer Genomics program at the Stanford Cancer Institute. Ash has a significant history of research and accomplishments in cancer genomics, beginning with the original development of microarray gene expression profiling for cancer classification, starting with lymphomas and advancing to multiple tumor types. In close collaboration with Dr. Maximilian Diehn’s group, his research group at Stanford University has a long history of developing cancer genomic techniques, including the ultrasensitive and noninvasive detection of tumor-derived cell-free DNA. Clinically, he is a practicing medical oncologist specializing in the care of patients with lymphoma, including diffuse large B-cell lymphoma (DLBCL). His clinical research is focused on diagnostic, prognostic, and predictive biomarkers and translating discoveries from the laboratory to the clinic using cutting-edge tools in data science.